<SEC-DOCUMENT>0001558370-20-011409.txt : 20201007
<SEC-HEADER>0001558370-20-011409.hdr.sgml : 20201007
<ACCEPTANCE-DATETIME>20201007171537
ACCESSION NUMBER:		0001558370-20-011409
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201007
FILED AS OF DATE:		20201007
DATE AS OF CHANGE:		20201007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		201229636

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20201007x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/7/2020 09:15:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF OCTOBER 2020</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28<br></b><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background-color:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background-color:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background-color:#ffffff;">Form&#160;S-8</font><font style="background-color:#ffffff;">&#160;(File&#160;No.&#160;333-232693)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: October 7, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.1127167%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated October 7, 2020: Grant of Restricted Stock Units and Warrants to Employees in Genmab</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20201007xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/7/2020 09:15:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20201007xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Grant of Restricted Stock Units and Warrants to Employees in Genmab</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Copenhagen, Denmark; October 7, 2020 &#8211; Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">the board </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">decided to grant 14,187 restricted stock units and 43,941 warrants to employees of the company and three of the company&#39;s subsidiaries.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,317. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The restricted stock units will vest on the first banking day of the month following a period of t</font><a name="OpenAt"></a><font style="font-family:'Arial','Helvetica','sans-serif';">hree years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the Remuneration Policy adopted by the shareholders at the annual general meeting. Information concerning Genmab&#8217;s restricted stock unit program can be found on </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.genmab.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> under </font><font style="font-family:'Arial','Helvetica','sans-serif';">Investors &gt; Stock information &gt; Restricted stock units.</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The exercise price for each warrant is DKK 2,317. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 748.02.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab&#8217;s warrant schemes can be found on </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.genmab.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> under </font><font style="font-family:'Arial','Helvetica','sans-serif';">Investors &gt; Stock information &gt; Warrants</font><font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174; </sup><font style="font-family:'Arial','Helvetica','sans-serif';">(teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO&#8482; (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab&#39;s technology base consists of validated and proprietary next generation antibody technologies - the DuoBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform for generation of bispecific antibodies, the HexaBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which creates effector function enhanced antibodies, the HexElect</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 43</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20201007xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Grant of Restricted Stock Units and Warrants to Employees in Genmab</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Contact:</b></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Corporate Vice President, Communications &amp; Investor Relations </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E: </font><font style="font-family:'Arial','Helvetica','sans-serif';">mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For Investor Relations: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Senior Director, Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: </font><font style="font-family:'Arial','Helvetica','sans-serif';">acn@genmab.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:10pt;"><a name="_Hlk34743654"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Company Announcement contains forward looking statements. The words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">www.genmab.com</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and the risk factors included in Genmab&#8217;s </i><font style="font-size:10pt;"><a name="_Hlk35592020"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">most recent Annual Report on Form 20-F </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and other filings </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody in combination with the DuoBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">HexaBody in combination with</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">the HexaBody logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; and UniBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">. Arzerra</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and Kesimpta</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174; </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">are trademarks of Novartis AG or its affiliates. DARZALEX</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and DARZALEX FASPRO&#8482; are trademarks of Janssen Pharmaceutica NV. TEPEZZA</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> is a trademark of Horizon Therapeutics plc.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 43</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20201007xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20201007xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: 2\# 2(  A$! Q$!_\0
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2IJ5;KE2LC;#87EE[6<N:1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
